These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7802851)

  • 1. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
    O'Sullivan GH; Noshirvani H; Başoğlu M; Marks IM; Swinson R; Kuch K; Kirby M
    Br J Psychiatry; 1994 Jul; 165(1):79-86. PubMed ID: 7802851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.
    Noyes R; DuPont RL; Pecknold JC; Rifkin A; Rubin RT; Swinson RP; Ballenger JC; Burrows GD
    Arch Gen Psychiatry; 1988 May; 45(5):423-8. PubMed ID: 3358644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation reactions to alprazolam in panic disorder.
    Pecknold JC
    J Psychiatr Res; 1993; 27 Suppl 1():155-70. PubMed ID: 8145176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
    Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
    J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto.
    Marks IM; Swinson RP; Başoğlu M; Kuch K; Noshirvani H; O'Sullivan G; Lelliott PT; Kirby M; McNamee G; Sengun S
    Br J Psychiatry; 1993 Jun; 162():776-87. PubMed ID: 8101126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
    Bond AJ; Curran HV; Bruce MS; O'Sullivan G; Shine P
    J Affect Disord; 1995 Dec; 35(3):117-23. PubMed ID: 8749839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse.
    Başoğlu M; Marks IM; Kiliç C; Brewin CR; Swinson RP
    Br J Psychiatry; 1994 May; 164(5):652-9. PubMed ID: 7921716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder.
    Curran HV; Bond A; O'Sullivan G; Bruce M; Marks I; Lelliot P; Shine P; Lader M
    Psychol Med; 1994 Nov; 24(4):969-76. PubMed ID: 7892364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia.
    Spiegel DA; Roth M; Weissman M; Lavori P; Gorman J; Rush J; Ballenger J
    Br J Psychiatry; 1993 Jun; 162():788-9; discussion 790-4. PubMed ID: 8101127
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
    Schweizer E; Patterson W; Rickels K; Rosenthal M
    Am J Psychiatry; 1993 Aug; 150(8):1210-5. PubMed ID: 8328566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance drug therapy of panic disorder.
    Curtis GC; Massana J; Udina C; Ayuso JL; Cassano GB; Perugi G
    J Psychiatr Res; 1993; 27 Suppl 1():127-42. PubMed ID: 8145175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure.
    Başoğlu M; Marks IM; Swinson RP; Noshirvani H; O'Sullivan G; Kuch K
    J Affect Disord; 1994 Feb; 30(2):123-32. PubMed ID: 7911132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
    Başoğlu M; Marks IM; Kiliç C; Swinson RP; Noshirvani H; Kuch K; O'Sullivan G
    Br J Psychiatry; 1994 May; 164(5):647-52. PubMed ID: 7921715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panic disorder with agoraphobia.
    Klein DF
    Br J Psychiatry; 1993 Dec; 163():835-7. PubMed ID: 7905776
    [No Abstract]   [Full Text] [Related]  

  • 18. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
    Maier W; Roth SM; Argyle N; Buller R; Lavori P; Brandon S; Benkert O
    Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):151-8. PubMed ID: 1790160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo.
    Cassano GB; Toni C; Petracca A; Deltito J; Benkert O; Curtis G; Hippius H; Maier W; Shera D; Klerman G
    Eur Neuropsychopharmacol; 1994 Mar; 4(1):47-53. PubMed ID: 8204996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alprazolam in panic disorder: a retrospective analysis.
    Shelton RC; Harvey DS; Stewart PM; Loosen PT
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 May; 17(3):423-34. PubMed ID: 8475324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.